Brean Capital analyst Difei Yang recommends using the "slow decline" in shares of Syneron Medical (ELOS) over the past two months as a buying opportunity into the company's Q2 results. The analyst has "high confidence" that UltraShape unit sales will meet her forecast of 55 units in Q2. Doing so would bring investors, Yang tells investors in a research note. She points out that the recent acquisition multiple of competitor Lumenis (LMNS) would put Syneron shares at $14 without the UltraShape business. The stock closed yesterday up 1c to $9.86. Yang reiterates a Buy rating on Syneron with an $18 price target.